News NICE green light a win for Lilly in RA market RA drug backed after manufacturer offered discount.
News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
Views & Analysis Will UK patients get access to novel drugs? Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F... Lilly's drug will be re-appraised in 2020
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
